PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: €77.50 through €148.50
VIP Peptide EU – Buy Online | In Stock & Ready to Ship
Buy VIP Peptide in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for VIP Peptide Europe suppliers, looking to buy VIP Peptide in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
VIP (Vasoactive Intestinal Peptide) is a 28 amino acid endogenous neuropeptide and immunomodulatory hormone, available to buy in Europe for laboratory research into neuroimmune regulation, gut motility biology, pulmonary physiology, circadian rhythm signalling, and VPAC receptor pharmacology.
Laboratories and research institutions across the EU can order verified, research-grade VIP with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA)
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch to EU & Europe | Tracked Shipping
VIP (Vasoactive Intestinal Peptide) is a 28 amino acid neuropeptide and peptide hormone belonging to the glucagon/secretin superfamily — a structurally related class of signalling peptides sharing a conserved helical backbone that includes PACAP, glucagon, GLP-1, secretin, and PHI. First isolated from porcine intestine in 1970 by Said and Mutt, VIP is now understood to be one of the most widely distributed and pleiotropic neuropeptides in the body — expressed throughout the enteric nervous system, central and peripheral nervous system, immune tissues, respiratory tract, and reproductive organs.
VIP exerts its biological effects through two G-protein coupled receptors — VPAC1 and VPAC2 — both of which signal primarily through Gs-coupled cAMP/PKA pathways and are expressed in a wide range of tissues including intestinal smooth muscle, immune cells, lung, brain, pancreas, and cardiovascular tissue. A third receptor — PAC1 — preferentially binds PACAP but shows some VIP affinity at higher concentrations, adding further complexity to VIP’s receptor pharmacology. Through these receptors, VIP coordinates an extraordinarily broad range of physiological functions — earning its characterisation in the research literature as one of the most multifunctional neuropeptides known.
VIP’s biological roles span gut motility regulation, vasodilation and bronchodilation, immune tolerance induction, circadian clock synchronisation in the suprachiasmatic nucleus, neurotransmission, exocrine and endocrine secretion, and reproductive biology — making it a research tool of relevance across gastroenterology, immunology, pulmonology, chronobiology, and neuroscience. Its potent anti-inflammatory and immunomodulatory properties have attracted particular research attention — with studies establishing VIP as a key mediator of immune tolerance through effects on T regulatory cell induction, Th1/Th2 balance, and innate immune cell cytokine suppression. These properties have made VIP one of the most actively researched immunomodulatory neuropeptides in European pre-clinical research settings.
In laboratory settings, VIP is studied across an exceptionally broad range of physiological systems and research applications — reflecting its wide tissue distribution and pleiotropic receptor pharmacology. EU and European researchers working with VIP typically focus on:
All research applications are for in vitro and pre-clinical use only.
VIP has one of the most extensive research literatures of any neuropeptide — with over five decades of investigation spanning gastroenterology, immunology, neuroscience, pulmonology, and chronobiology establishing it as a pleiotropic signalling molecule of fundamental physiological importance.
Immunomodulatory profile: A large and well-established body of research has characterised VIP as a potent anti-inflammatory and immunomodulatory neuropeptide — documenting suppression of TNF-α, IL-6, IL-12, and IL-1β production in stimulated macrophages and dendritic cells, induction of IL-10 and TGF-β tolerogenic cytokines, promotion of regulatory T cell differentiation, and inhibition of Th1 and Th17 inflammatory responses. These findings have established VIP as one of the primary mediators of neuroimmune anti-inflammatory regulation and have driven substantial European research interest in VIP as a model immunomodulatory neuropeptide.
Autoimmune disease pre-clinical research: Studies examining VIP in pre-clinical autoimmune models have documented beneficial effects across multiple disease systems — including reductions in joint inflammation and cartilage damage in collagen-induced arthritis models, improvements in neurological parameters in EAE multiple sclerosis models, and reductions in intestinal inflammation in colitis models. These findings have characterised VIP’s therapeutic research potential across autoimmune biology and have positioned it as a reference neuropeptide immunomodulator in European pre-clinical research.
Circadian biology: Research has established VIP as the essential neurotransmitter for synchronising circadian rhythms between SCN neurons — with studies documenting that VIP/VPAC2 signalling maintains the coherent circadian oscillation of the SCN clock network that drives daily rhythms in physiology and behaviour. Studies using VIP knockout and VPAC2 knockout models have comprehensively characterised the consequences of disrupted VIP signalling for circadian rhythm organisation — establishing VIP as an indispensable research tool in chronobiology.
Enteric nervous system research: Decades of research have characterised VIP as a major inhibitory neurotransmitter of the enteric nervous system — with studies documenting its role in descending inhibition during peristalsis, non-adrenergic non-cholinergic (NANC) relaxation of intestinal smooth muscle, and coordination of gut motility patterns. This foundational gastrointestinal neuroscience literature has established VIP as the reference compound for studying inhibitory enteric neurotransmission.
Pulmonary research: Studies have characterised VIP expression in pulmonary neurons and its bronchodilatory and anti-inflammatory effects in airway tissue — with research documenting VPAC receptor-mediated smooth muscle relaxation, inhibition of mast cell activation, and suppression of airway inflammatory responses. Reduced VIP expression has been documented in asthmatic airways in some research, connecting VIP biology to inflammatory respiratory disease research.
Neuroprotection research: Studies have characterised VIP’s neuroprotective effects in models of CNS injury and neurodegeneration — documenting protection against excitotoxic, ischaemic, and inflammatory neuronal injury through mechanisms including BDNF upregulation, anti-apoptotic signalling, and microglial activation suppression. These findings have established VIP as a research tool for studying neuropeptide-mediated CNS protection.
VPAC receptor signalling characterisation: Research has comprehensively characterised VPAC1 and VPAC2 receptor distribution, binding kinetics, downstream cAMP/PKA signalling cascades, and differential tissue expression — with VIP serving as the primary pharmacological tool for these studies. This receptor biology literature provides the mechanistic foundation for interpreting VIP’s diverse physiological effects across different tissue systems.
| Compound | Type | Primary Receptors | Key Research Application |
|---|---|---|---|
| VIP | 28aa endogenous neuropeptide | VPAC1 + VPAC2 | Neuroimmune regulation, gut motility, circadian biology, pulmonary research |
| PACAP-38 | 38aa neuropeptide — VIP superfamily | PAC1 + VPAC1 + VPAC2 | Neuroprotection, stress biology, comparative VPAC/PAC1 pharmacology |
| PACAP-27 | 27aa PACAP truncation | PAC1 + VPAC1 + VPAC2 | Comparative PACAP biology, receptor selectivity research |
| Secretin | 27aa — VIP superfamily | Secretin receptor | Pancreatic secretion, gut biology |
| KPV | α-MSH C-terminal tripeptide | Melanocortin pathway / NF-κB | Gut inflammation, anti-inflammatory biology |
| Thymosin β4 | 43aa thymic peptide | Pleiotropic repair signalling | Tissue repair, immune regulation |
Every order of VIP peptide dispatched to EU and European research institutions includes:
Yes. We supply research-grade Vasoactive Intestinal Peptide with fast tracked international dispatch to all EU member states and wider European destinations including Germany, France, Netherlands, Spain, Italy, Poland, and beyond. Packaging is designed to maintain peptide integrity throughout transit and all orders include full batch documentation. VIP is supplied strictly for laboratory research use only.
VPAC1 and VPAC2 are both G-protein coupled receptors that bind VIP and PACAP with comparable affinity — signalling primarily through Gs-coupled cAMP/PKA pathways. They differ in their tissue distribution and physiological roles. VPAC1 is widely expressed — found in lung, intestine, liver, immune cells, and throughout the CNS — and is considered the primary mediator of VIP’s immunomodulatory effects given its expression on T cells, macrophages, and dendritic cells. VPAC2 has a more restricted distribution — expressed prominently in the suprachiasmatic nucleus, smooth muscle, pancreas, and specific brain regions — and is the primary receptor mediating VIP’s circadian rhythm synchronisation function in the SCN. These distinct distributions make VPAC1 and VPAC2 research targets of interest in different biological contexts, with VIP serving as the reference non-selective agonist for both.
VIP and PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) are closely related members of the glucagon/secretin superfamily with overlapping but distinct receptor pharmacology. Both bind VPAC1 and VPAC2 with comparable affinity, but PACAP additionally binds PAC1 — a receptor with much higher affinity for PACAP than VIP — through which it exerts many of its most characterised neuroprotective and stress biology effects. VIP’s research profile is more centred on immunomodulation, gut biology, and circadian rhythm regulation — reflecting its high expression in enteric neurons, immune tissues, and the SCN. PACAP’s research profile emphasises neuroprotection, stress response biology, and CNS signalling — reflecting PAC1 receptor expression in brain regions involved in these functions. The two are studied as complementary tools for dissecting the shared VPAC1/VPAC2 pharmacology from the PACAP-selective PAC1 receptor biology.
The suprachiasmatic nucleus (SCN) — the brain’s master circadian clock — contains approximately 20,000 neurons that must synchronise their individual circadian oscillations to produce a coherent population-level rhythm driving daily physiological cycles. VIP, released by a subset of SCN neurons, binds VPAC2 receptors on neighbouring neurons to synchronise their circadian clocks through cAMP/PKA signalling — maintaining the phase coherence of the SCN network. Research using VIP knockout and VPAC2 knockout mice has documented severe circadian rhythm fragmentation and arrhythmicity — establishing VIP/VPAC2 signalling as essential for SCN network synchronisation. VIP is therefore the primary research tool for studying the neurotransmitter mechanisms underlying circadian clock network organisation.
VIP’s immunomodulatory profile makes it one of the most pharmacologically interesting endogenous anti-inflammatory neuropeptides for autoimmune disease research. Its effects include suppression of pro-inflammatory cytokines through VPAC1 on immune cells, promotion of regulatory T cell differentiation, inhibition of Th17 inflammatory responses, and induction of tolerogenic dendritic cell phenotypes — collectively shifting immune responses toward tolerance. In pre-clinical autoimmune models including arthritis, multiple sclerosis, and inflammatory bowel disease, VIP administration has produced measurable reductions in disease parameters. These findings position VIP as a reference neuropeptide immunomodulator for studying neuroimmune regulation and as a research model for peptide-based immune tolerance strategies.
VIP is one of the primary inhibitory neurotransmitters of the enteric nervous system — released from inhibitory motor neurons to drive relaxation of intestinal smooth muscle through VPAC receptor-mediated cAMP elevation and downstream smooth muscle hyperpolarisation. It plays an essential role in the descending inhibition component of the peristaltic reflex — where intestinal contents trigger relaxation ahead of the advancing bolus — and in non-adrenergic non-cholinergic (NANC) relaxation of gut smooth muscle. VIP-containing enteric neurons are among the most well-characterised in gut neuroscience, and VIP is used as the reference inhibitory enteric neurotransmitter in research examining intestinal smooth muscle pharmacology, peristaltic reflex mechanisms, and enteric nervous system circuit biology.
Allow the vial to reach room temperature before opening. Add sterile water or an appropriate laboratory buffer slowly down the vial wall and swirl gently — do not shake. VIP is a 28 amino acid peptide that reconstitutes in aqueous buffers — prepare at your protocol’s required concentration and consider adding a carrier protein such as BSA at low concentrations to minimise adsorption losses. Aliquot and store at -80°C to minimise freeze-thaw degradation. Standard peptide handling protocols apply. VIP is susceptible to enzymatic degradation — prepare working solutions fresh and handle on ice during experimental procedures.
Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to protect peptide stability throughout transit.
| Parameter | Detail |
|---|---|
| Full Name | Vasoactive Intestinal Peptide |
| Type | Endogenous 28 Amino Acid Neuropeptide — Glucagon/Secretin Superfamily |
| Primary Receptors | VPAC1 + VPAC2 (Gs-coupled cAMP/PKA signalling) |
| Molecular Weight | 3326.8 g/mol |
| Primary Research Interest | Neuroimmune regulation, gut motility, circadian biology, pulmonary research, autoimmune models |
| Purity | ≥99% |
| Verification | HPLC & Mass Spectrometry |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water or laboratory buffer — BSA carrier recommended at low concentrations |
| Storage | -20°C, protected from light and moisture |
| Intended Use | Research use only |
VIP (Vasoactive Intestinal Peptide) is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.
Receive News
